LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trialD. Schadendorf, E. Livingstone, Lidija Kandolf Sekulović et al.|Annals of Oncology|2024Cited by 3